Table 1.
Demographic characteristics and clinical data of subjects
| Variable | +Stripe (n = 18) (%) | −Stripe (n = 13) (%) | P value |
|---|---|---|---|
| Female | 2 (11) | 8 (62) | 0.006 |
| Age | 42 + 16 | 50 + 12 | 0.14 |
| CAD | 0 | 0 | 1.0 |
| Tobacco | 5 (27.8) | 5 (38.5) | 0.7 |
| HTN | 6 (33.3) | 7 (53.8) | 0.44 |
| Diabetes | 2 (11.1) | 1 (7.7) | 1.0 |
| CVA | 0 | 1 (7.7) | 0.42 |
| Family history of CMP | 1 (5.6) | 2 (15.4) | 0.56 |
| COPD/asthma | 4 (22.2) | 3 (23.1) | 1.0 |
| PE/hypercoagulable | 3 (16.7) | 0 | 0.25 |
| OSA | 2 (11.1) | 0 | 0.497 |
| GERD | 3 (16.7) | 2 (15.4) | 1.0 |
| Alcohol | 4 (22.2) | 2 (15.4) | 1.0 |
| Hypothyroidism | 2 (11.1) | 2 (15.4) | 1.0 |
| Medications | |||
| Beta blocker | 13 (72.2) | 12 (92.3) | 0.36 |
| ACE inhibitor | 18 (100) | 12(92.3) | 0.42 |
| ARB | 0 | 2 (15.4) | 0.17 |
| Aldosterone antagonist | 11 (61.1) | 6 (46.2) | 0.41 |
| Digoxin | 6 (33.3) | 4 (30.8) | 1.0 |
| Furosemide | 14 (77.8) | 7 (53.8) | 0.25 |
| Statin | 3 (16.7) | 4 (30.8) | 0.41 |
| Hydralazine‐nitrate | 1 (5.6) | 2 (15.4) | 0.56 |
| Allopurinol | 0 | 1 (7.7) | 0.42 |
| Amiodarone | 3 (16.7) | 0 | 0.25 |
Data presented are means ± SD. ACE inhibitors: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; CAD denotes: coronary artery disease; CMP: cardiomyopathy; COPD: chronic obstructive pulmonary disease; CVA: cerebro‐vascular disease; ETOH: alcohol; GERD: gastro‐esophageal reflux disease; OSA: obstructive sleep apnoea; PE: pulmonary embolism; HTN: hypertension.